Kiromic Biopharma, Inc. Business Operations Contracts & Agreements
9 Contracts & Agreements
- Collaboration Agreements (2 contracts)
- Indemnification Agreements (3)
- Services Agreements (1)
- Settlement Agreements (2)
- Voting Agreements (1)
- Amended Stipulation of Settlement and Mutual Release, dated October 27, 2022, by and among Kiromic Biopharma, Inc., Empery Asset Master, Ltd. and other parties (Filed With SEC on November 2, 2022)
- Stipulation of Settlement and Mutual Release, dated October 10, 2022, by and among Kiromic Biopharma, Inc., Empery Asset Master, Ltd. and other parties (Filed With SEC on October 14, 2022)
- Indemnification Agreement effective as of February 14, 2022, by and between Kiromic BioPharma, Inc. and Daniel Clark (Filed With SEC on February 16, 2022)
- Indemnification Agreement effective as of January 27, 2022 by and between Kiromic BioPharma, Inc. and Pietro Bersani (Filed With SEC on February 2, 2022)
- Form of Director Indemnification Agreement, to be effective upon initial public offering, between Kiromic BioPharma, Inc. and all independent directors (Filed With SEC on June 26, 2020)
- Form of Director Services Agreement, to be effective upon initial public offering, between Kiromic BioPharma, Inc. and all independent directors (Filed With SEC on June 26, 2020)
- Collaboration Agreement, dated February 6, 2020, between University of Texas MD Anderson Cancer Center and Kiromic BioPharma, Inc (Filed With SEC on May 11, 2020)
- Collaboration Agreement, dated February 4, 2019, between University of Texas MD Anderson Cancer Center and Kiromic BioPharma, Inc (Filed With SEC on May 11, 2020)
- Voting Agreement, dated September 7, 2019, among Kiromic BioPharma, Inc., certain investors and certain stockholders (Filed With SEC on May 11, 2020)
